Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | F13A1 | P00488 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913996 | 1.00 | MAPT (0.49) | MAPTRAB9ALMNAMDM2TTR | |
| SCHEMBL1511462 | 0.82 | MAPT (0.49) | MAPTRAB9ALMNAMDM2TTR | |
| SCHEMBL1511465 | 0.82 | MAPT (0.49) | MAPTRAB9ALMNAMDM2TTR | |
| SCHEMBL16379028 | 0.79 | TTR (0.42) | MAPTRAB9ALMNAMDM2TTR | |
| SCHEMBL16379025 | 0.78 | MAPT (0.46) | MAPTRAB9ALMNAMDM2TTR | |
| SCHEMBL6263496 | 0.78 | MAPT (0.57) | MAPTRAB9ALMNAMDM2TTR | |
| SCHEMBL6263498 | 0.78 | MAPT (0.57) | MAPTRAB9ALMNAMDM2TTR | |
| SCHEMBL8698401 | 0.77 | GPR52 (0.51) | LMNAGPR52ALDH1A1HCAR2 | |
| SCHEMBL8698403 | 0.77 | GPR52 (0.51) | LMNAGPR52ALDH1A1HCAR2 | |
| SCHEMBL8647200 | 0.77 | RAB9A (0.64) | MAPTRAB9ALMNAMDM2TTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9233911-B2 | Cu-mediated annulation for the production of 1-amino-2-naphthalenecarboxylic acid derivatives | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-12 | — | — | US | disclosed |
| US-9233911-B2 | Cu-mediated annulation for the production of 1-amino-2-naphthalenecarboxylic acid derivatives | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-01-12 | — | — | US | disclosed |
| US-20150011781-A1 | Cu-Mediated Annulation for the Production of 1-Amino-2-Naphthalenecarboxylic Acid Derivatives | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-01-08 | — | — | US | disclosed |
| US-20150011781-A1 | Cu-Mediated Annulation for the Production of 1-Amino-2-Naphthalenecarboxylic Acid Derivatives | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-01-08 | — | — | US | disclosed |
| WO-2013105117-A1 | Cu-MEDIATED ANNULATION FOR THE PRODUCTION OF 1-AMINO-2-NAPHTHALENECARBOXYLIC ACID DERIVATIVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-18 | — | — | WO | disclosed |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | ROGEL OLIVIER | 2009-10-01 | — | — | US | disclosed |
| EP-2029544-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007140980-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011781-A1 | Cu-Mediated Annulation for the Production of 1-Amino-2-Naphthalenecarboxylic Acid Derivatives | DDC, AOC2, AOC1 | MAPT 1886/4885RAB9A 3952/4885LMNA 2844/4885 |
| US-20090247577-A1 | PYRROLIDINE DERIVATIVES USEFUL AS BACE INHIBITORS | BACE1, BACE2, APP | MAPT 15/4885RAB9A 1703/4885LMNA 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.